OncoSec Selected to Present Data at Upcoming Head and Neck Cancer Conferences
New Analysis of Phase III and IV Head & Neck Cancer Results
SAN DIEGO, March 22, 2012 /PRNewswire/ -- OncoSec Medical Incorporated. (OTCBB:ONCS), which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that the company has been selected to present data from its Phase III and IV head and neck cancer studies at two upcoming conferences. Data from the Phase IV study carried out in Europe has been selected for a poster session and special oral presentation at the 5th European Conference on Head and Neck Oncology. In addition, data from the Phase III study carried out in the United States has been selected for a poster presentation at the 8th International Head and Neck Cancer Conference.
OncoSec's most advanced stage treatment platform, OMS ElectroChemotherapy, is a targeted ablation therapy, which utilizes the OMS to locally deliver bleomcyin to the tumor. This treatment platform preferentially kills targeted cancer cells while sparing surrounding normal healthy tissue. OMS ElectroChemotherapy has been developed up to Phase III clinical trials in the United States for the treatment of recurrent head and neck cancer and in Phase I/II for the treatment of recurrent breast cancer. In addition, Phase IV pre-marketing studies to support the commercialization of the OMS system in Europe were also performed for the treatment of primary and recurrent head and neck cancers and cutaneous skin cancers.
"Since acquiring the OMS ElectroChemotherapy assets in March 2011, we have been working diligently to compile and analyze data from the Phase III and IV studies carried out in the United States and Europe. We are excited that we will now have the opportunity to share this data with the public in the coming months," said Punit Dhillon , President and CEO. "With this data, we expect to finalize our clinical development plan and move forward with commercializing the OMS ElectroChemotherapy platform with a partner, either regionally or globally."
The Phase IV head and neck cancer results, carried out in Europe, will be presented at:
The 5th European Conference on Head and Neck Oncology
April 18-21, 2012
Special Poster Session and Presentation
"Interim analysis of an open labeled, single arm multicenter study of electrochemotherapy in recurrent head and neck cancer"
The 8th International Head and Neck Cancer Conference
Toronto Convention Center
July 21-25, 2012
"Interim analysis of two randomized Phase 3 trials comparing electrochemotherapy to surgery in recurrent head and neck cancer"
About OMS ElectroChemotherapy
Through its asset acquisition, OncoSec has accumulated a significant database of clinical data in a variety of tumor types using the OMS ElectroChemotherapy therapeutic approach.Â To date OMSÂ ElectroChemotherapy has been tested in several clinical trials ranging from Phase I through Phase IV conducted in 13 countries across over 50 sites.Â Human data has been collected in over 400 patients with cancers ranging from basal and squamous cell carcinomas, melanoma, adenocarcinoma, Kaposi's sarcoma, pancreatic, hepatic, oral, and head and neck cancers.Â OMS ElectroChemotherapy utilizes electroporation to locally deliver the chemotherapeutic drug bleomycin to treat solid tumors. A distinctive feature of the OMS ElectroChemotherapy treatment platform is both the preservation of healthy tissue and killing of cancerous cells in the lesion and at the margins of the tumor. It is anticipated that the system may therefore afford advantages over surgery in preserving function and improving the quality of life for cancer patients who would otherwise face significant morbidity associated with cancer surgery or other treatment modalities.
About Head and Neck Cancer
Most head and neck cancers are found in people over age 40. Men are two to three times more likely than women to have head and neck cancer, although rates in women have been rising along with their growing use of tobacco and alcohol. The number of new cases of head and neck cancers in the United States was 70,490 in 2008, accounting for about 3% of adult malignancies and the worldwide incidence exceeds half a million cases annually. It is estimated that approximately $3.1 billion is spent in the United States each year on treatment for head and neck cancers. Head and neck cancers encompass a diverse group of uncommon tumors that frequently are aggressive in their biologic behavior. Moreover, patients with a head and neck cancer often develop a second primary tumor, in part secondary to common risk factors. In North America and Europe, the tumors usually arise from the oral cavity, oropharynx, or larynx, whereas nasopharyngeal cancer is more common in the Mediterranean countries and in the Far East. In Southeast China and Taiwan, head and neck cancer, specifically nasopharyngeal cancer is the most common cause of death in young men.
About OncoSec Medical Inc.
OncoSec Medical Incorporated isÂ a biopharmaceutical companyÂ developing its advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers and metastatic disease.Â OMS ElectroOncology therapiesÂ address an unmet medical needÂ andÂ representÂ a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives. Â OncoSec's core technology is based upon its proprietaryÂ use of anÂ electroporation platform,Â theÂ OncoSec Medical System (OMS),Â toÂ dramatically enhanceÂ theÂ delivery and uptake of a locally delivered DNA-based immuno-cytokine (OMS ElectroImmunotherapy) or chemotherapeutic agentsÂ (OMS ElectroChemotherapy). Treatment ofÂ various solid cancersÂ using these powerfulÂ and targetedÂ anti-cancer agentsÂ has demonstratedÂ selective destruction of cancerous cellsÂ while sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy targeting lethal skin cancers. More information is available at www.oncosec.com. Additional information may also be found at OncoSec's Facebook, Twitter, and LinkedIn sites.
This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
SOURCE OncoSec Medical Incorporated
Released March 22, 2012